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Cases of multiple chemical sensitivity (MCS)
are characterized by a series of puzzling features
described by multiple research groups and
individuals (Ashford and Miller 1998; Cullen
1987; Johnson 2000; Miller and Mitzel 1995;
Rea 1992; Sorg 1999; Ziem and McTamney
1997). Although they are typically preceded by
and presumably induced by exposure of the
individual to one or more chemicals, there is
no accepted view as to how those chemicals
may act in inducing MCS. Chemical sensitiv-
ity appears to be progressive, increasing with
increasing chemical exposure; however, there is
no accepted mechanism by which such pro-
gressive sensitization may occur. The symp-
toms reported to be induced by chemical
exposure in MCS patients are similar to those
characteristic of chronic fatigue syndrome
(CFS), but no plausible mechanism has been
proposed as to how those symptoms are gener-
ated by such chemical exposure. Sensitivity to
a wide variety of chemicals has been reported
in MCS, most notably volatile organic solvents
and organophosphates and other acetyl-
cholinesterase inhibitors, but it is unclear why
these types of compounds produce such sen-
sitivity. Sensitivity is chronic, apparently
decreasing slowly over time when MCS indi-
viduals avoid chemical exposure; however,
there is no indication that this leads to a com-
plete recovery for the condition, leaving the
puzzle of why MCS is chronic. There are mul-
tiple overlaps between MCS and three related
conditions—CFS, fibromyalgia (FM), and
posttraumatic stress disorder (PTSD)—with
both overlapping symptoms and the number
of people being diagnosed with more than
one of these disorders (Pall 2001b, 2002b).
However, it is not clear why these overlaps
occur.
In this article, I discuss a proposed etio-
logic mechanism that provides attractive solu-
tions to each of the above-described puzzles.
Such solutions do not allow us to infer that
this proposal is necessarily correct, but they do
suggest that we should look at it carefully.
This mechanism was discussed previously in a
different context (Pall 2002b) and goes to the
heart of the most central puzzle of MCS: How
can previous chemical exposure generate the
exquisite chemical sensitivity reported in
MCS, often two or more orders of magnitude
greater sensitivity than is seen in normal peo-
ple? Such sensitivity is shown, for example,
when an MCS patient reports sensitivity to
the perfume worn by someone walking by
them, but the perfume wearer herself shows
little sensitivity. Cullen (1987) suggested a
sensitivity of two orders of magnitude as a
diagnostic feature of MCS. The previous lack
of any physiologically plausible mechanism for
generating such exquisite sensitivity has been
one of the weak points of the CFS literature.
The exquisite chemical sensitivity mecha-
nism proposed here is not only an extension
of the previous elevated nitric oxide/peroxyni-
trite theory of MCS, but also shares the cen-
tral tenets of the neural sensitization theory of
MCS etiology (Bell et al. 1992, 1996, 1999)
that were the focus of the recent New York
Academy of Science volume on neural sensiti-
zation and MCS (Bell and Sorg 2001).
The Elevated Nitric
Oxide/Peroxynitrite Theory
The most wide-ranging theory of MCS and
related conditions CFS, FM, and PTSD is the
elevated nitric oxide/peroxynitrite theory,
which was ﬁrst proposed for CFS (Pall 2000a,
2000b, 2001a, 2002a; Smirnova and Pall
2003), and later extended to the other three
conditions (Pall 2001b; Pall and Satterlee
2001). The theory as it applies to CFS will be
brieﬂy discussed, followed by a discussion of
how it may extend to these other overlapping
conditions. Most CFS cases are preceded by
an infectious episode. The infection is pro-
posed (Pall 2000a) to induce inflammatory
cytokines, which induce, in turn, the
inducible nitric oxide synthase, which pro-
duces elevated levels of nitric oxide. Nitric
oxide reacts with superoxide to form the
potent oxidant peroxynitrite. Peroxynitrite
acts, in turn, through known biochemical
mechanisms to increase the levels of both its
precursors, nitric oxide and superoxide, thus
generating chronically elevated peroxynitrite
(Pall 2000a). In this way, a biochemical
vicious cycle may be initiated and maintained,
characterized by excessive levels of nitric oxide
and peroxynitrite. The classic symptoms of
CFS can be generated by plausible mecha-
nisms involving nitric oxide, peroxynitrite,
and other consequences of this proposed
mechanism (Pall 2000b). Furthermore, the
proposed mechanism is supported by 13 dif-
ferent biochemical/physiological observations
(Pall 2000a, 2000b, 2001a, 2002a; Smirnova
and Pall 2003). One treatment commonly
used to treat CFS and also used to treat some
cases of FM and MCS involves intramuscular
or subcutaneous vitamin B12 and vitamin B12
in the form of hydroxocobalamin, a potent
nitric oxide scavenger both in vitro and in vivo
(Pall 2001a).
A pattern of evidence derived from studies
of patients and animal models suggests that
the elevated nitric oxide/peroxynitrite theory
can be extended to MCS, FM, and PTSD
(Pall 2001b; Pall and Satterlee 2001). Where
differences in symptoms occur, these may be
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Research | Articlecaused partly by variation in tissue distribution
of the underlying biochemistry.
Fusion of the Nitric
Oxide/Peroxynitrite 
Theory with the Neural
Sensitization Theory of MCS
As discussed above, neural sensitization was
first proposed by Bell et al. (1992, 1996,
1998, 1999) as a central mechanism in MCS,
and such neural sensitization is produced by
the process of long-term potentiation (LTP).
LTP has been most studied in the hippocam-
pus, where it involves stimulation of the
N-methyl-D-aspartate (NMDA) receptors. It
is well known that NMDA stimulation pro-
duces increased levels of both nitric oxide and
peroxynitrite (Haley et al. 1990; Lafon Cazal
et al. 1993; Murray et al. 1991; Reynolds and
Hastings 1995). It may be immediately seen
from this that the neural sensitization theory
overlaps with the nitric oxide/peroxynitrite
theory. Furthermore, nitric oxide has an
important role in LTP, acting as a retrograde
messenger (Bliss and Collingridge 1993; Prast
and Phillipu 2001; Snyder 1992), increasing
the release of neurotransmitters including glu-
tamate, which in turn stimulate the NMDA
receptors. Thus, we have a potential vicious
cycle in the nervous system, with excessive
NMDA activity producing excessive nitric
oxide leading to excessive NMDA activity
(Figure 1). Furthermore the peroxynitrite
product of nitric oxide depletes ATP pools via
two different mechanisms (Boczkowski et al.
2001; Szabo and Billiar 1999), and when cells
containing NMDA receptors become ATP
depleted, these receptors become hypersen-
sitive to stimulation (Novelli et al. 1988;
Schultz et al. 1997; Turski and Turski 1993).
Thus, there is potential for additional input
into the proposed vicious cycle, with nitric
oxide producing increased NMDA stimula-
tion and peroxynitrite producing increased
NMDA receptor sensitivity (Figure 1).
Normally, LTP is thought to be triggered
on a highly selective basis in learning and
memory, increasing the sensitivity and activity
of specific synapses. If chemical stimulation
produces increased nitric oxide and peroxyni-
trite in large regions of the brain, the diffusion
of these compounds over several cell diameters
from their sites of synthesis could lead to mas-
sive neural hyperactivity and hypersensitivity.
So how may chemicals feed into these pro-
posed mechanisms? As discussed above, two
classes of chemicals are implicated in the initi-
ation of cases of MCS: organophosphate and
carbamate pesticides and hydrophobic organic
solvents. The pesticides here are known acetyl-
cholinesterase inhibitors, leading to increased
levels of acetylcholine. Acetylcholine stimu-
lation of muscarinic receptors will produce
increases in nitric oxide, as discussed earlier
(Pall 2002b; Pall and Satterlee 2001), thus
feeding into the proposed NMDA mechanism
(Figure 1). There are three suggested roles for
hydrophobic organic solvents; two are predicted
to produce increases in nitric oxide, and one is
predicted to lead to decreased ATP synthesis
(Pall 2002b), any of which may lead into the
proposed mechanism (Figure 1, arrows with
question marks). Thus, although the target(s) of
action of hydrophobic organic solvents is uncer-
tain, several plausible targets are consistent with
the overall mechanism discussed above.
The major evidence supporting the above-
described mechanism includes 10 types of evi-
dence supporting the nitric oxide/peroxynitrite
theory of MCS (Pall 2002b; Pall and Satterlee
2001); 10 “remarkable similarities” between
neural sensitization and MCS (Ashford and
Miller 1998); and ﬁve types of evidence suggest-
ing NMDA hyperactivity in MCS (Pall 2002b).
Two accessory mechanisms are also sug-
gested to be involved in MCS, one involving
nitric oxide and the other peroxynitrite:nitric
oxide inhibition of cytochrome P450 activity
and peroxynitrite-mediated increased perme-
ability of the blood–brain barrier (BBB) (Pall
2002b; Pall and Satterlee 2001). Each of these
is expected to lead to increased chemical sen-
sitivity through decreased metabolism of
hydrophobic chemicals and increased accessibil-
ity of chemicals to the central nervous system
(CNS), respectively. Consequently, after initia-
tion of increased NMDA receptor activity,
nitric oxide levels, and peroxynitrite levels by
organic solvent exposure, four mechanisms are
expected to act synergistically to produce the
exquisite chemical sensitivity reported in MCS:
• Increased neurotransmitter (glutamate)
release stimulated by nitric oxide acting as a
retrograde messenger
• Increased NMDA sensitivity, produced by
peroxynitrite via postsynaptic ATP deple-
tion and consequent increased sensitivity of
NMDA receptors
• Nitric oxide inhibition of cytochrome P450s,
leading to decreased degradation of organic
solvents
• Peroxynitrite-mediated increased BBB per-
meability, leading to increased access of
chemicals to the CNS.
It should be noted that Abou-Donia et al.
(2001) reported increased permeability of the
BBB in an animal model of MCS.
Relation to Other Previous
Hypotheses of MCS
As mentioned above, the NMDA/nitric
oxide/peroxynitrite view of MCS is derived
partly from both the elevated nitric oxide/per-
oxynitrite and the neural sensitization theories
of MCS. However, it may also be compatible
with evidence supporting two other views of
MCS.
The nitric oxide/peroxynitrite biochem-
istry proposed to underlie the current mecha-
nism is basically inflammatory, i.e., induced
by inflammatory cytokines and found at the
sites of inﬂammation in many overtly inﬂam-
matory conditions. Therefore, the mechanism
proposed above may be related to and possibly
linked to the neurogenic inﬂammation mecha-
nism suggested by Meggs and coworkers to be
involved in MCS (Bascom et al. 1997; Meggs
1993, 1995). Evidence for a causal role of
nitric oxide in such neurogenic inﬂammation
has been reported by several groups (Kajekar
et al. 1995; Ruocco et al. 2001; Yonehara and
Yoshimura 1999), providing important sup-
port for this view. Furthermore, mast cell
degranulation, an important aspect of the neu-
rogenic inﬂammation mechanism, is reported
to be stimulated by nitric oxide and/or peroxy-
nitrite (Deschoolmeester et al. 1999; Forsyth
et al. 2001; Kawauchi et al. 2001; Konopka et
al. 2001). These observations provide some
support for the view that a possible role of
neurogenic inflammation in MCS may be
seen as a consequence of elevated nitric oxide
and peroxynitrite.
An additional type of aberrant biochem-
istry that may be implicated in MCS concerns
evidence for elevated levels of porphyrin path-
way intermediates and their products, as well
as possible low levels of porphyrin pathway
enzymes (Downey 2001; Matthews 1998;
Morton 1997; Ziem and McTamney 1997;
see also Hahn and Bonkovsky 1997). These
observations have led to the proposal that
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Figure 1. Potential vicious cycle mechanism and
MCS. The top two-thirds of the figure represents
the potential stimulatory interactions leading to a
potential vicious cycle involving excessive NMDA
sensitivity and stimulation and excessive nitric
oxide and peroxynitrite. Arrows leading from the
lower regions represent proposed actions of





















?MCS may be a form of porphyria. My com-
ments here will be limited to two of the more
puzzling features of the porphyrin/MCS obser-
vations—apparently several intermediates of the
porphyrin pathway tend to accumulate in MCS,
and several of the pathway biosynthetic enzymes
tend to be low (Downey 2001; Matthews 1998;
Morton 1997; Ziem and McTamney 1997).
This pattern is distinguished from what may be
viewed as classical porphyria produced either
by mutation of one of the genes encoding a
biosynthetic enzyme in the porphyrin pathway
or in lead toxicity (Jacob et al. 1999), each of
which are limited to lowered activity of a single
enzyme in the pathway. Is there a mechanism
whereby elevated nitric oxide/peroxynitrite
might be expected to lead to a deﬁciency in sev-
eral porphyrin biosynthetic enzymes? There
may be such a mechanism. Most porphyrin
synthesis is located in either the liver or blood-
forming tissue, and blocks in either of these
may lead to symptoms of porphyria. Reports
show that nitric oxide leads to loss of some of
these porphyrin biosynthetic enzymes (Kim et
al. 1995; Rafferty et al. 1996), suggesting that
nitric oxide may interact with a regulatory
mechanism regulating the synthesis of these
enzymes. One speciﬁc mechanism that may be
particularly relevant to the blood-forming cells
is the control of the initiation factor eIF2 by
phosphorylation, which is stimulated by nitric
oxide, thus leading to decreased protein synthe-
sis, presumably including the porphyrin biosyn-
thetic enzymes (Uma et al. 2001). The nitric
oxide/eIF2 mechanism cited here may be
accompanied by a more specific mechanism.
The last enzyme in the porphyrin biosynthetic
pathway is ferrochelatase, an iron-sulfur pro-
tein (Dailey et al. 2000), and such iron-sulfur
proteins are inactivated by peroxynitrite. It is
possible, therefore, that a combination of
mechanisms involving nitric oxide and perox-
ynitrite may lead to lowered levels of several
porphyrin biosynthetic enzymes, leading, in
turn, to accumulation of porphyrin precursors
and their side products.
Evidence supporting four different views of
MCS centered on nitric oxide/peroxynitrite,
neural sensitization, neurogenic inﬂammation,
and porphyrin pathway aberrations may be
compatible with the NMDA/nitric oxide/per-
oxynitrite view presented here, and this may be
a way of integrating a variety of observations
into a single view of this condition.
Explanations for Puzzling
Features of MCS
This hypothesis involving excessive nitric
oxide and peroxynitrite and NMDA hyperac-
tivity provides answers to many of the most
puzzling questions about MCS:
• How is the exquisite sensitivity to chemicals
produced in MCS? Previous chemical expo-
sure produces increases in nitric oxide and
peroxynitrite in the nervous system, leading to
four interacting and synergistic mechanisms
of sensitivity: a) nitric oxide inhibition of
cytochrome P450 activity; b) peroxynitrite-
mediated increased permeability of the BBB;
c) nitric oxide stimulation of neurotransmitter
(glutamate) release, leading to increase
NMDA activity; and d) peroxynitrite-medi-
ated ATP depletion and consequent increased
sensitivity of NMDA receptors.
• How do chemicals initiate MCS and exacer-
bate the symptoms characteristic of MCS?
Such chemicals act via two neurotransmis-
sion systems, both of which increase nitric
oxide levels, with organic solvents acting
through the nitric oxide/peroxynitrite, and
NMDA receptors and pesticides including
organophosphates and carbamates acting
through the muscarinic receptors. These
same neurotransmitter systems may act both
in initiation of MCS and in upregulating
the symptoms of MCS.
• Why is MCS chronic? The multiple positive
feedback loops are proposed to act such that
once peroxynitrite levels are elevated, they
may remain elevated. Synaptic changes pro-
duced by LTP are also long-lasting and
therefore these may produce chronic effects
as well.
• How does chemical exposure generate the
characteristic symptoms of MCS? These
symptoms are similar to the chronic symp-
toms of CFS and may be generated by the
same mechanisms proposed for CFS—by
elevated levels of nitric oxide, peroxynitrite,
and other associated biochemical changes
(Pall 2000b).
• Why does MCS overlap with other condi-
tions, including CFS, FM, and PTSD? These
may all be proposed to have an identical cen-
tral etiologic mechanism involving elevated
nitric oxide/peroxynitrite, albeit with some-
what different tissue distribution, leading to
some variation in symptoms.
• How should MCS be treated? In addition to
avoidance of chemical exposure, treatments
might include the use of antioxidants to
lower the consequences of peroxynitrite ele-
vation and lower action of the positive feed-
back loops; drugs and nutrients to lower the
activity of NMDA and muscarinic receptors;
and oxygen and other therapies that could




Our knowledge of MCS has been mainly a
product of observational studies by a number
of dedicated physicians who described in
detail the case histories of thousands of
patients. These studies have raised many of the
puzzling issues discussed above. However,
unlike most areas of modern medicine, there
has been very little in the way of hypothesis-
driven research, largely because of a lack of any
overarching hypothesis or theory susceptible
to experimental test. The lack of such a theory
has also led some to disparage the inferences
drawn from careful observational studies.
Various predictions of the proposed nitric
oxide/peroxynitrite/NMDA view of CFS are
testable, and it is my hope that they will help
motivate hypothesis-driven research to test
some of these predictions.
As stated by Alfred North Whitehead,
mathematician and philosopher, “Seek simplic-
ity but distrust it.” We may have made a start
in seeking here, but have not yet proceeded to
distrust.
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